Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia

Introduction Acute lymphoblastic leukemia (ALL) is the most common cancer among children. Measurable residual disease (MRD, previously named minimal residual disease) study can guide therapy adjustments or preemptive interventions that might avoid hematological relapse. Methods Clinical decision mak...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2024-01, Vol.26 (1), p.278-287
Main Authors: Ramos Elbal, Eduardo, Fuster, Jose Luis, Campillo, José A., Galera, Ana María, Cortés, Mar Bermúdez, Llinares, María Esther, Jiménez, Irene, Plaza, Mercedes, Martínez Banaclocha, Helios, Galián, José Antonio, Blanquer Blanquer, Miguel, Martínez Sánchez, María Victoria, Muro, Manuel, Minguela, Alfredo
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Research Article
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Acute lymphoblastic leukemia (ALL) is the most common cancer among children. Measurable residual disease (MRD, previously named minimal residual disease) study can guide therapy adjustments or preemptive interventions that might avoid hematological relapse. Methods Clinical decision making and patient outcome were evaluated in 80 real-life childhood ALL patients, according to the results observed in 544 bone marrow samples analyzed with three MRD methods: multiparametric flow cytometry (MFC), fluorescent in-situ hybridization (FISH) on B or T-purified lymphocytes and patient-specific nested reverse transcription polymerase chain reaction (RT-PCR). Results Estimated 5 year overall survival and event-free survival were 94% and 84.1%, respectively. A total of 12 relapses in 7 patients were associated with positive MRD detection with at least one of the three methods: MFC ( p  
ISSN:1699-3055
1699-3055
DOI:10.1007/s12094-023-03251-0